Jingsong Wang, MD, PhD, is CEO of Harbour Biomed. Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang earned his PhD in Molecular Pharmacology from China Pharmaceutical University and also completed a Molecular Immunology Research Fellowship at the Harvard School of Public Health.

Prof. Xu has leaded the conduct of over ten phase I clinical trials regarding chemical class 1.1 new drugs, including Adefovir Dipivoxil, APG-1387, GB222, Recombinant Human Anti-PD-1 Monoclonal Antibody Injection, Morphothiadin Methanesulfonate and RO7239958. In addition, Prof. Xu won a Guangdong Joint Fund Project of the National Natural Science Foundation in 2015 as a co-applicant. He also participated in two Scientific and Technological Projects of Guangdong Province as a major participant, and leaded one Scientific and Technological Project of Guangzhou. Recently, Prof. Xu has published a number of articles on cancer and autophagy in Cell Death & Disease (IF 5.91), Appl Microbiol Biotechnol (IF 3.33), etc.

Hannah started her own business as a consultant after retired from JNJ in Feb. 2019. Hannah has worked for pharmaceutical industry for more than 20 years (GSK: May 1997 ~Sep 2012; JNJ: Sep 2012 ~ Jan 2019), where she developed various expertise including clinical operation: study monitoring, trial management, protocol design, draft clinical study report and training; GCP audit including investigator site, local operating company, external service provider; GCLP and PV audit; clinical Quality Management System training, set up and refinement; Training on Risk-based monitoring etc.

Dr. Liu is VP and Head of M&A Management at Tigermed Co. Ltd, a global CRO focused on clinical development. Her recent 1.5-year role involves finding and acquiring well-matching partners for Tigermed's global service platform. With 29 years of experience in clinical research and development for global pharmaceutical companies and CROs, she has managed Phase I-IV studies across multiple therapeutic areas. Jessica is trained in Clinical Medicine and has a post-graduate diploma in Pharmaceutical Medicine from the University of Basel. She has also dedicated much of her personal time to DIA China development.

Director, Ethics Committee Office, Renji Hospital, Shanghai Jiaotong University School of Medicine, Deputy Secretary-General, Shanghai Medical Ethics SocietyMember and Secretary, Shanghai, Medical Association, Research Ethics Branch, Member, DIA Advisory Council of China

Dr. Xia Fan is now Head of Biostatistics of Zai Lab, a leading biotech company in China. Before joining Zai Lab, Dr. Xia worked in R&D departments of BeiGene and Roche, and supported China local and multi-regional registrational oncology trials of multiple molecules as lead statistician or as therapeutic area lead. Besides regular work, Dr. Xia is also dedicated to pharmaceutical statistics methodology innovation and training in China. She is a YMAC of DIA China and a member of CSCO biostatistics society, and also owns a popular WeChat subscription account “XiaFan_Blog”.

Jing CHEN graduated in Pharmaceutical from China Pharmaceutical University and has been working as a QA professional in Pharmaceutical industry since February 2004. Being the mainstay in the QA team in China, she has over 16 years’ QA and auditing experience with AstraZeneca, Quintiles and UCB. Her experiences spans GCP, GCLP and GMP regulated area in both Asia Pacific and Europe. She is now QA Director with LinkStart, and is responsible for the delivery of Quality Assurance and training activities within the company.

Yue WANG is Vice President of ClinPlus, the leading SMO in China. Yue has more than 9 years experience in clinical research operations, over 4 years experience of nursing in Canada. She handled about 20+ multinational projects, including Phase II, Phase III study, Phase IV Study, etc., related to the diseases of Endocrinology, Oncology, Infection, Cardiovascular, etc. Yue is Vice Chair of DIA China SMO Community and once was Young Member, Advisory Council of China, DIA Yue owns CCRC (Certified clinical research coordinator), IACRN